Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $4.00.

MCRB has been the topic of several research analyst reports. The Goldman Sachs Group lowered their target price on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research note on Friday, March 14th. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Thursday, March 20th. Finally, StockNews.com downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday.

Seres Therapeutics Trading Up 8.3 %

Shares of MCRB stock opened at $0.58 on Tuesday. The company has a market capitalization of $101.23 million, a price-to-earnings ratio of -2.52 and a beta of 2.54. Seres Therapeutics has a 1-year low of $0.46 and a 1-year high of $1.53. The stock’s fifty day simple moving average is $0.73 and its 200-day simple moving average is $0.79.

Institutional Trading of Seres Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 222,771 shares in the last quarter. FMR LLC increased its position in Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares during the last quarter. State Street Corp raised its holdings in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 255,014 shares during the last quarter. Finally, Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.